Abiopharma

Viridian Therapeutics, Inc. - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Director Kauffman Michael 🟢 acquired 200.0K shares (1 derivative) of Verastem, Inc. (VSTM) at $6.88 ($1.4M) Transaction Date: Jan 06, 2026 | Filing ID: 002117

Inspira Technologies Oxy BHN (IINNW) Files Form 6-K

Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues

Senseonics Announces First Commercial Patients Using Eversense 365 Continuous Glucose Monitor (CGM) with twiist™ Automated Insulin Delivery (AID) System

Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026

Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis

Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)

LILLY ENDOWMENT INC 🔴 sold 292.1K shares of ELI LILLY & Co (LLY) at $1,116.69 ($322.4M) Transaction Date: Jan 07, 2026 | Filing ID: 000003

Director jeereddi Prasad Anjaneya 🟢 acquired 3.6K shares of Elite Health Systems Inc. (EHSI) at $1.43 Transaction Date: Jan 06, 2026 | Filing ID: 000881

New SEC Form for ResMed Inc.

Organon conclut un accord de commercialisation pour Nilemdo® de Daiichi Sankyo en France, au Danemark, en Islande, en Suède, en Finlande et en Norvège

Director Farrell Michael J. 🟡 adjusted position in 5.0K shares (1 derivative) of RESMED INC (RMD) at $248.46 ($2.7M) Transaction Date: Jan 07, 2026 | Filing ID: 000003

Organon sluit een akkoord voor de commercialisering van Daiichi Sankyo’s Nilemdo® in Frankrijk, Denemarken, IJsland, Zweden, Finland en Noorwegen

Organon sottoscrive un accordo di commercializzazione relativo a Nilemdo® di Daiichi Sankyo in Francia, Danimarca, Islanda, Svezia, Finlandia e Norvegia